Testim Makers Opt To Settle Following Axiron Settlement

Testim Makers Opt To Settle Following Axiron Settlement

Introduction

Closely following the heels of the Eli Lilly settlement announcement to resolve all Axiron lawsuits belonging to the MDL 2545 earlier this year, the makers of Testim gel have now reached an agreement to settle all Testim Lawsuits. The defendants named in the Testim lawsuits are Auxilium Pharmaceuticals, Endo Pharmaceuticals, and GlaxoSmithKline and this move would resolve more than 1,300 cases filed by men who suffered heart attacks, strokes and blood clots due to their use of Testim gel.

MDL No. 2545 when consolidated in June 2014 before U.S. District Judge Matthew Kennelly in the U.S. District Court for the Northern District of Illinois eventually grew to a size of more than 6,000 lawsuits. The Axiron and Testim settlements are expected to reduce the total number by one-third.

A 45-day stay has been issued for all cases pending against the Testim manufacturers so that the details of the still-undisclosed settlement could be finalized under a Master Settlement Agreement. The forthcoming bellwether trial dates for April 6 and September 10 were vacated by the court. The Testim defendants have made it clear that the settlement will not involve any admission of wrongdoing or liability.